Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1725–1730. doi: 10.1128/aac.41.8.1725

Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

W A Krueger 1, G Ruckdeschel 1, K Unertl 1
PMCID: PMC163993  PMID: 9257749

Abstract

Ciprofloxacin, when given intravenously (i.v.), is secreted in significant amounts via the mucosa into the intestinal lumen. Sucralfate inhibits the antimicrobial activity of ciprofloxacin. The effect of combined therapy on the intestinal flora was investigated in 16 healthy volunteers. They were randomly assigned to two groups. Group A received 2 g of sucralfate orally three times a day for 7 days and 400 mg of ciprofloxacin i.v. twice a day (b.i.d.) starting 3 days after the sucralfate administration began. Group B was given only 400 mg of ciprofloxacin i.v. b.i.d. for 4 days. A total of 9 stool samples were collected from each subject beginning the week before ciprofloxacin was administered and on days -1, 1, 2, 3, 4, 7, 9, and 10 or 11 after commencement of the infusion period. The aerobic fecal flora was determined by standard microbiological methods. Measurements of fecal ciprofloxacin levels were based on high-performance liquid chromatography. Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2) CFU/g in eight of eight subjects (group A) and six of eight subjects (group B) on day 4, but they returned to normal in all but one subject (group A) 10 days after the last infusion. The decreases in levels of bacteria of the family Enterobacteriaceae were not significantly different in groups A and B (Kaplan-Meier test). Staphylococci and nonfermenters responded variably, enterococci and lactobacilli remained unchanged, and candida levels increased transiently in four subjects (two in each group). Maximum fecal drug levels ranged from 251 to 811 microg/g. No significant difference could be found between the two groups. The i.v. application of ciprofloxacin eliminates intestinal bacteria of the family Enterobacteriaceae in a rapid and selective manner. This effect is not affected by simultaneous oral application of sucralfate.

Full Text

The Full Text of this article is available as a PDF (271.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergan T., Delin C., Johansen S., Kolstad I. M., Nord C. E., Thorsteinsson S. B. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother. 1986 Feb;29(2):298–302. doi: 10.1128/aac.29.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergmans D., Bonten M., Gaillard C., van Tiel F., van der Geest S., Stobberingh E. In vitro antibacterial activity of sucralfate. Eur J Clin Microbiol Infect Dis. 1994 Jul;13(7):615–620. doi: 10.1007/BF01971318. [DOI] [PubMed] [Google Scholar]
  3. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drusano G. L. An overview of the pharmacology of intravenously administered ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):339–345. [PubMed] [Google Scholar]
  5. Dörner A., Witthohn A., Kraas E. Ciprofloxacin prior to colon surgery. Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):177–179. doi: 10.1016/0732-8893(90)90105-5. [DOI] [PubMed] [Google Scholar]
  6. Edlund C., Lindqvist L., Nord C. E. Norfloxacin binds to human fecal material. Antimicrob Agents Chemother. 1988 Dec;32(12):1869–1874. doi: 10.1128/aac.32.12.1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Folkman J., Szabo S., Stovroff M., McNeil P., Li W., Shing Y. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg. 1991 Oct;214(4):414–427. doi: 10.1097/00000658-199110000-00006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Garrelts J. C., Godley P. J., Peterie J. D., Gerlach E. H., Yakshe C. C. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 1990 May;34(5):931–933. doi: 10.1128/aac.34.5.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Griffiths N. M., Hirst B. H., Simmons N. L. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J Pharmacol Exp Ther. 1994 May;269(2):496–502. [PubMed] [Google Scholar]
  10. Hollander D., Tarnawski A. The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1–5. doi: 10.3109/00365529009091917. [DOI] [PubMed] [Google Scholar]
  11. Holt H. A., Lewis D. A., White L. O., Bastable S. Y., Reeves D. S. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. Eur J Clin Microbiol. 1986 Apr;5(2):201–205. doi: 10.1007/BF02013987. [DOI] [PubMed] [Google Scholar]
  12. Jaehde U., Sörgel F., Reiter A., Sigl G., Naber K. G., Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther. 1995 Nov;58(5):532–541. doi: 10.1016/0009-9236(95)90173-6. [DOI] [PubMed] [Google Scholar]
  13. Kappstein I., Engels I. Antibacterial activity of sucralfate and bismuth subsalicylate in simulated gastric fluid. Eur J Clin Microbiol. 1987 Apr;6(2):216–217. doi: 10.1007/BF02018225. [DOI] [PubMed] [Google Scholar]
  14. Kilburn K. H., Warshaw R. H. Pulmonary functional impairment from years of arc welding. Am J Med. 1989 Jul;87(1):62–69. doi: 10.1016/s0002-9343(89)80484-x. [DOI] [PubMed] [Google Scholar]
  15. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy. 1988;8(1):3–33. doi: 10.1002/j.1875-9114.1988.tb04058.x. [DOI] [PubMed] [Google Scholar]
  16. Lehto P., Kivistö K. T. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):248–251. doi: 10.1128/aac.38.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lubowski T. J., Nightingale C. H., Sweeney K., Quintiliani R. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. Antimicrob Agents Chemother. 1992 Dec;36(12):2758–2760. doi: 10.1128/aac.36.12.2758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nix D. E., Watson W. A., Handy L., Frost R. W., Rescott D. L., Goldstein H. R. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy. 1989;9(6):377–380. doi: 10.1002/j.1875-9114.1989.tb04152.x. [DOI] [PubMed] [Google Scholar]
  19. Parpia S. H., Nix D. E., Hejmanowski L. G., Goldstein H. R., Wilton J. H., Schentag J. J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother. 1989 Jan;33(1):99–102. doi: 10.1128/aac.33.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pecquet S., Ravoire S., Andremont A. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother. 1990 Jul;26(1):125–129. doi: 10.1093/jac/26.1.125. [DOI] [PubMed] [Google Scholar]
  21. Ramon J., Dautrey S., Farinoti R., Carbon C., Rubinstein E. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob Agents Chemother. 1994 Apr;38(4):757–760. doi: 10.1128/aac.38.4.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Robertson J. A., Salusky I. B., Goodman W. G., Norris K. C., Coburn J. W. Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. Ann Intern Med. 1989 Jul 15;111(2):179–181. doi: 10.7326/0003-4819-111-2-179. [DOI] [PubMed] [Google Scholar]
  23. Rohwedder R. W., Bergan T., Thorsteinsson S. B., Scholl H. Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):127–133. doi: 10.1016/0732-8893(90)90095-d. [DOI] [PubMed] [Google Scholar]
  24. Rozenberg-Arska M., Dekker A. W., Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis. 1985 Jul;152(1):104–107. doi: 10.1093/infdis/152.1.104. [DOI] [PubMed] [Google Scholar]
  25. Rubinstein E., Dautrey S., Farinoti R., St Julien L., Ramon J., Carbon C. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob Agents Chemother. 1995 Jan;39(1):99–102. doi: 10.1128/aac.39.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rubinstein E., St Julien L., Ramon J., Dautrey S., Farinotti R., Huneau J. F., Carbon C. The intestinal elimination of ciprofloxacin in the rat. J Infect Dis. 1994 Jan;169(1):218–221. doi: 10.1093/infdis/169.1.218. [DOI] [PubMed] [Google Scholar]
  27. Scholl H., Schmidt K., Weber B. Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. J Chromatogr. 1987 May 15;416(2):321–330. doi: 10.1016/0378-4347(87)80515-7. [DOI] [PubMed] [Google Scholar]
  28. Szabo S. The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7–12. doi: 10.3109/00365529109093214. [DOI] [PubMed] [Google Scholar]
  29. Tanimura H., Tominaga S., Rai F., Matsumoto H. Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. Arzneimittelforschung. 1986 Sep;36(9):1417–1420. [PubMed] [Google Scholar]
  30. Tellez A., Sainz C., Echevarria C., de Carlos S., Fernandez M. V., Leon P., Brezina R. Q fever in Spain: acute and chronic cases, 1981-1985. Rev Infect Dis. 1988 Jan-Feb;10(1):198–202. doi: 10.1093/clinids/10.1.198. [DOI] [PubMed] [Google Scholar]
  31. Viell B., Krause B., Vestweber K. H., Schaaf S., Scholl H. Transintestinal elimination of ciprofloxacin in humans--concomitant assessment of its metabolites in serum, ileum and colon. Infection. 1992 Nov-Dec;20(6):324–327. doi: 10.1007/BF01710676. [DOI] [PubMed] [Google Scholar]
  32. Yuk J. H., Nightingale C. N., Quintiliani R. Ciprofloxacin levels when receiving sucralfate. JAMA. 1989 Aug 18;262(7):901–901. [PubMed] [Google Scholar]
  33. Zeiler H. J., Petersen U., Gau W., Ploschke H. J. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneimittelforschung. 1987 Feb;37(2):131–134. [PubMed] [Google Scholar]
  34. van Saene J. J., van Saene H. K., Lerk C. F. Inactivation of quinolone by feces. J Infect Dis. 1986 May;153(5):999–1000. doi: 10.1093/infdis/153.5.999. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES